apnimed

Eli Lilly reported second-quarter revenue of $23 billion, a 48% increase year over year, driven by soaring demand for its GLP-1 medications Mounjaro and Zepbound, according to the company’s earnings report. The pharmaceutical giant subsequently raised its annual revenue guidance to a range between $85 billion and $87 billion, pushing its stock price up nearly … Read more